Biotechnology companies

EXEL Exelixis, Inc. Exelixis sells cancer drugs, led by CABOMETYX, and is building its next drug franchise around zanzalintinib. #1 of 132 · Finn Score 3.9/5 HALO Halozyme Therapeutics, Inc. Halozyme licenses drug delivery tech that helps big biotech drugs move from IV infusions to under-the-skin shots. #2 of 132 · Finn Score 3.9/5 ASND Ascendis Pharma A/S Ascendis makes long-acting rare endocrine drugs using its TransCon platform. #3 of 132 · Finn Score 3.7/5 INCY Incyte Corporation Incyte makes cancer and immune disease drugs, led by JAKAFI and OPZELURA. #4 of 132 · Finn Score 3.7/5 LQDA Liquidia Corporation Liquidia sells inhaled treprostinil for rare heart and lung diseases, balancing rapid commercial growth against existential patent lawsuits. #5 of 132 · Finn Score 3.6/5 HRMY Harmony Biosciences Holdings, Inc. Harmony sells WAKIX for narcolepsy and uses the cash to build a rare brain disease pipeline. #6 of 132 · Finn Score 3.6/5 CORT Corcept Therapeutics Incorporated Corcept sells cortisol-blocking drugs for Cushing's syndrome and ovarian cancer. #7 of 132 · Finn Score 3.6/5 TGTX TG Therapeutics, Inc. TG Therapeutics sells BRIUMVI, an infusion drug for relapsing multiple sclerosis. #8 of 132 · Finn Score 3.5/5 VRTX Vertex Pharmaceuticals Incorporated Vertex sells cystic fibrosis drugs and is building new medicines for pain, blood disease, kidney disease, diabetes, and endocrine diseases. #9 of 132 · Finn Score 3.5/5 TVTX Travere Therapeutics, Inc. Travere sells rare kidney disease drugs, led by FILSPARI, and is working to overcome new supply chain and regulatory challenges. #10 of 132 · Finn Score 3.5/5 JAZZ Jazz Pharmaceuticals plc Jazz sells rare disease drugs for sleep disorders, epilepsy, and cancer. #11 of 132 · Finn Score 3.5/5 REGN Regeneron Pharmaceuticals, Inc. Regeneron is a biotech company selling eye, allergy, inflammation, cancer, and rare disease medicines. #14 of 132 · Finn Score 3.4/5 ALNY Alnylam Pharmaceuticals, Inc. Alnylam makes RNAi medicines that silence disease genes, led by AMVUTTRA for ATTR amyloidosis. #17 of 132 · Finn Score 3.3/5 ONC BeOne Medicines AG BeOne Medicines develops cancer drugs worldwide, led by the blood cancer therapy BRUKINSA. #18 of 132 · Finn Score 3.3/5 ARQT Arcutis Biotherapeutics, Inc. Arcutis sells ZORYVE skin disease treatments and is expanding the brand across more patients and doctors. #19 of 132 · Finn Score 3.3/5 TARS Tarsus Pharmaceuticals, Inc. Tarsus sells XDEMVY for Demodex blepharitis and is building a broader pipeline in eye care and Lyme disease prevention. #20 of 132 · Finn Score 3.2/5 PTGX Protagonist Therapeutics, Inc. Protagonist discovers peptide medicines and relies on partners like J&J and Takeda to launch its lead drugs. #22 of 132 · Finn Score 3.2/5 BMRN BioMarin Pharmaceutical Inc. BioMarin makes high-price medicines for rare genetic diseases. #23 of 132 · Finn Score 3.2/5 GMAB Genmab A/S Genmab is a Danish biotech that makes antibody cancer drugs and earns large royalties from partner-sold medicines. #24 of 132 · Finn Score 3.2/5 VCEL Vericel Corporation Vericel sells cell therapies for knee cartilage repair and severe burns. #25 of 132 · Finn Score 3.1/5 ACAD ACADIA Pharmaceuticals Inc. ACADIA sells CNS drugs for Parkinson's disease psychosis and Rett syndrome. #26 of 132 · Finn Score 3.1/5 TECH Bio-Techne Corporation Bio-Techne sells research reagents and diagnostic tools, but is currently pending a cash acquisition by Merck KGaA. #27 of 132 · Finn Score 3.1/5 URGN UroGen Pharma Ltd. UroGen sells bladder and urinary tract cancer drugs built around its RTGel drug delivery platform. #28 of 132 · Finn Score 3.0/5 CAI Caris Life Sciences, Inc. Caris sells cancer profiling tests and data services that help doctors and drug companies choose better treatments. #30 of 132 · Finn Score 2.9/5 MESO Mesoblast Limited Mesoblast makes donor-derived cell medicines for severe inflammatory diseases. #32 of 132 · Finn Score 2.9/5 MRNA Moderna, Inc. Moderna makes mRNA vaccines and medicines, led by COVID, RSV, and flu programs. #33 of 132 · Finn Score 2.8/5 LEGN Legend Biotech Corporation Legend Biotech makes cell therapies, led by CARVYKTI for multiple myeloma. #38 of 132 · Finn Score 2.7/5 ADPT Adaptive Biotechnologies Corporation Adaptive sells clonoSEQ cancer monitoring tests and plans to separate its immune medicine unit. #40 of 132 · Finn Score 2.7/5 MRVI Maravai LifeSciences Holdings, Inc. Maravai sells mRNA, nucleic acid, and biologics safety tools for drug, vaccine, and diagnostic makers. #41 of 132 · Finn Score 2.6/5 INSM Insmed Incorporated Insmed sells inhaled and oral medicines for serious lung diseases, led by BRINSUPRI and ARIKAYCE. #47 of 132 · Finn Score 2.5/5 BNTX BioNTech SE BioNTech is the mRNA vaccine maker using COVID profits to build a cancer drug business. #51 of 132 · Finn Score 2.5/5 IONS Ionis Pharmaceuticals, Inc. Ionis makes RNA-targeted drugs and is shifting to direct sales following a major clinical setback for a key partnered drug. #53 of 132 · Finn Score 2.5/5 ZLAB Zai Lab Limited Zai Lab commercializes approved drugs in Greater China while accelerating a global oncology pipeline. #57 of 132 · Finn Score 2.5/5 PTCT PTC Therapeutics, Inc. PTC Therapeutics sells rare disease drugs, led by the growing launch of Sephience for PKU. #59 of 132 · Finn Score 2.5/5 AXSM Axsome Therapeutics, Inc. Axsome sells and develops brain and nervous system medicines, led by Auvelity for depression and Alzheimer’s agitation. #60 of 132 · Finn Score 2.5/5 AGIO Agios Pharmaceuticals, Inc. Agios sells rare blood disease drugs built around mitapivat and is seeking approval in sickle cell disease. #63 of 132 · Finn Score 2.4/5 NKTR Nektar Therapeutics Nektar is a clinical-stage biotech developing immune drugs for autoimmune disease and cancer. #70 of 132 · Finn Score 2.4/5 IBRX ImmunityBio, Inc. ImmunityBio sells ANKTIVA for bladder cancer and is trying to turn it into a wider cancer treatment platform. #72 of 132 · Finn Score 2.3/5 MIRM Mirum Pharmaceuticals, Inc. Mirum sells rare disease drugs, led by liver and bile acid medicines, while building new pipeline shots. #74 of 132 · Finn Score 2.3/5 BBIO BridgeBio Pharma, Inc. BridgeBio sells rare disease drugs, led by Attruby for ATTR-CM, and is preparing to launch three more. #79 of 132 · Finn Score 2.3/5 QURE uniQure N.V. uniQure is a clinical-stage gene therapy developer built around AMT-130 for Huntington's disease. #83 of 132 · Finn Score 2.3/5 KYMR Kymera Therapeutics, Inc. Kymera develops oral protein-degrading drugs, mostly for immune diseases, with no approved products yet. #88 of 132 · Finn Score 2.2/5 ROIV Roivant Sciences Ltd. Roivant builds drug companies around clinical assets, mainly in inflammation and immunology. #90 of 132 · Finn Score 2.2/5 BEAM Beam Therapeutics Inc. Beam is a pre-commercial biotech using base editing to build one-time genetic medicines. #91 of 132 · Finn Score 2.2/5 CRSP CRISPR Therapeutics AG CRISPR Therapeutics builds gene-editing and gene-based medicines, led by CASGEVY with Vertex. #94 of 132 · Finn Score 2.2/5 CYTK Cytokinetics, Incorporated Cytokinetics sells and develops muscle-directed drugs, led by MYQORZO for hypertrophic cardiomyopathy. #101 of 132 · Finn Score 2.1/5 RCUS Arcus Biosciences, Inc. Arcus is a clinical-stage biotech developing cancer and immune disease drugs, with no approved products yet. #102 of 132 · Finn Score 2.1/5 NAMS NewAmsterdam Pharma Company N.V. NewAmsterdam is a late-stage biotech built around obicetrapib, an oral drug aimed at lowering LDL cholesterol. #103 of 132 · Finn Score 2.1/5 RARE Ultragenyx Pharmaceutical Inc. Ultragenyx sells rare disease drugs and is awaiting two major gene therapy approval decisions in late 2026. #107 of 132 · Finn Score 2.1/5 NRIX Nurix Therapeutics, Inc. Nurix is a clinical-stage biotech building protein degrader drugs for cancer and immune disease. #116 of 132 · Finn Score 1.9/5 DNTH Dianthus Therapeutics, Inc. Dianthus is a clinical-stage biotech developing antibody drugs for severe autoimmune diseases. #117 of 132 · Finn Score 1.9/5 ABVX Abivax S.A. Abivax is a clinical-stage biotech built around obefazimod, an oral drug candidate for inflammatory bowel disease. Not ranked · Not scored ACLX Arcellx, Inc. Arcellx is a Gilead-owned biotech built around CAR-T cell therapies, led by anito-cel for multiple myeloma. Not ranked · Not scored AKRO Akero Therapeutics, Inc. Akero is a clinical-stage MASH biotech being acquired by Novo Nordisk. Not ranked · Not scored ALMS Alumis Inc. Alumis is a pre-revenue clinical-stage biotech company developing targeted immunology therapies, led by envu for plaque psoriasis. Not ranked · Not scored APGE Apogee Therapeutics, Inc. Apogee is a clinical-stage biotech focused on inflammatory diseases that has agreed to be acquired by AbbVie. Not ranked · Not scored APLS Apellis Pharmaceuticals, Inc. Apellis sells complement drugs for eye, blood, and kidney diseases, with value now tied to Biogen deal terms. Not ranked · Not scored ARGX argenx SE argenx is a rare disease biotech built around VYVGART, an antibody drug for immune nerve and muscle diseases. Not ranked · Not scored ARWR Arrowhead Pharmaceuticals, Inc. Arrowhead develops RNAi medicines that silence disease-driving genes, led by its approved drug REDEMPLO. Not ranked · Not scored ATAI Atai Beckley Inc. Atai Beckley is a clinical-stage mental health biotech company being acquired by Eli Lilly. Not ranked · Not scored BHVN Biohaven Ltd. Biohaven is a clinical-stage biotech testing treatments for immune, brain, cancer, and muscle diseases. Not ranked · Not scored BLTE Belite Bio, Inc Belite Bio is a clinical-stage biotech developing oral Tinlarebant for Stargardt disease and geographic atrophy. Not ranked · Not scored BPMC Blueprint Medicines Corp. Blueprint Medicines developed targeted drugs for mast cell disease, cancer, and inflammation. Not ranked · Not scored CDTX Cidara Therapeutics, Inc. Cidara is a clinical-stage biotech built around Cloudbreak drug-Fc conjugates, led by CD388 for flu prevention. Not ranked · Not scored CELC Celcuity Inc. Celcuity is a commercial-stage cancer drug company built around REVTORPYK for advanced breast cancer. Not ranked · Not scored CGON CG Oncology Inc. CG Oncology is a clinical-stage biotech developing cretostimogene for bladder cancer. Not ranked · Not scored CLDX Celldex Therapeutics, Inc. Clinical-stage biotech developing antibody drugs for severe allergic, inflammatory, and autoimmune diseases. Not ranked · Not scored CNTA Centessa Pharmaceuticals plc Centessa is a clinical-stage biotech now centered on Lilly’s pending buyout and a sleep-drug CVR. Not ranked · Not scored COGT Cogent Biosciences, Inc. Cogent is a biotech trying to turn its lead drug, bezuclastinib, into its first approved product in late 2026. Not ranked · Not scored CPRX Catalyst Pharmaceuticals, Inc. Catalyst sells rare disease drugs, led by FIRDAPSE for LEMS and AGAMREE for DMD. Not ranked · Not scored CRNX Crinetics Pharmaceuticals, Inc. Crinetics makes oral drugs for rare hormone diseases, led by PALSONIFY for acromegaly. Not ranked · Not scored DFTX Definium Therapeutics, Inc. Definium is a late-stage biotech testing psychedelic-based drugs for anxiety, depression, PTSD, and autism. Not ranked · Not scored DNLI Denali Therapeutics Inc. Denali is a commercial biotech company building brain-delivered drugs for rare and neurodegenerative diseases. Not ranked · Not scored DYN Dyne Therapeutics, Inc. Dyne is a clinical-stage biotech using its FORCE platform to deliver genetic medicines into muscle. Not ranked · Not scored ELVN Enliven Therapeutics, Inc. Enliven is a pre-revenue cancer drug developer focused on ELVN-001 for chronic myeloid leukemia. Not ranked · Not scored ERAS Erasca, Inc. Erasca is a clinical-stage cancer drug company focused on RAS and MAPK pathway tumors. Not ranked · Not scored ETNB 89bio, Inc. 89bio is a clinical-stage biotech built around pegozafermin for MASH and severe triglycerides. Not ranked · Not scored EWTX Edgewise Therapeutics, Inc. Edgewise is a clinical-stage biotech focused on EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for heart failure. Not ranked · Not scored FOLD Amicus Therapeutics, Inc. Amicus sells rare disease drugs for Fabry and Pompe disease, with a kidney disease drug in Phase 3. Not ranked · Not scored GLUE Monte Rosa Therapeutics, Inc. Monte Rosa develops molecular glue medicines that make disease proteins get destroyed inside the body. Not ranked · Not scored GPCR Structure Therapeutics Inc. Structure Therapeutics develops oral small molecule drugs, led by an obesity GLP-1 candidate. Not ranked · Not scored IDYA IDEAYA Biosciences, Inc. IDEAYA is a clinical-stage cancer drug developer focused on tumors with clear genetic targets. Not ranked · Not scored IMNM Immunome, Inc. Immunome is a biotech developing targeted cancer drugs, led by varegacestat for desmoid tumors. Not ranked · Not scored IMVT Immunovant, Inc. Immunovant is a clinical-stage biotech trying to treat autoimmune diseases by lowering harmful IgG antibodies. Not ranked · Not scored IOVA Iovance Biotherapeutics, Inc. Iovance sells personalized cancer cell therapy, led by Amtagvi for advanced melanoma. Not ranked · Not scored IRON Disc Medicine, Inc. Disc Medicine develops blood disease drugs, led by bitopertin for rare light sensitivity disorders. Not ranked · Not scored KOD Kodiak Sciences Inc. Kodiak is a clinical-stage biotech trying to build longer-lasting drugs for retinal diseases. Not ranked · Not scored KRYS Krystal Biotech, Inc. Krystal sells VYJUVEK, a redosable gene therapy gel, and uses that cash to build more HSV-1 genetic medicines. Not ranked · Not scored LGND Ligand Pharmaceuticals Incorporated Ligand buys and licenses drug royalties instead of running a full drug company. Not ranked · Not scored MANE Veradermics, Incorporated Veradermics is a pre-revenue biotech developing an oral minoxidil pill for pattern hair loss. Not ranked · Not scored MBX MBX Biosciences, Inc. Common Stock MBX is a clinical-stage biotech developing long-acting peptide drugs for endocrine and metabolic diseases, with a new focus on obesity. Not ranked · Not scored MDGL Madrigal Pharmaceuticals, Inc. Madrigal sells Rezdiffra, the first approved drug for certain NASH patients with liver scarring, and is building a follow-on pipeline. Not ranked · Not scored MLYS Mineralys Therapeutics, Inc. Mineralys is a clinical-stage biotech built around lorundrostat for high blood pressure and kidney disease. Not ranked · Not scored NBTX Nanobiotix S.A. Nanobiotix is a late-stage biotech using nanoparticles to make radiation hit tumors harder. Not ranked · Not scored NUVB Nuvation Bio Inc. Nuvation Bio develops and sells targeted cancer therapies, driven by its commercial ROS1 inhibitor IBTROZI. Not ranked · Not scored NUVL Nuvalent, Inc. Nuvalent develops targeted cancer pills for small, mutation-defined lung cancer groups. Not ranked · Not scored ORKA Oruka Therapeutics, Inc. Oruka is a clinical-stage biotech building longer-lasting antibody drugs for inflammatory skin diseases. Not ranked · Not scored PCVX Vaxcyte, Inc. Vaxcyte is a clinical-stage vaccine developer built around broad pneumococcal shots. Not ranked · Not scored PHVS Pharvaris N.V. Pharvaris is a late-stage rare disease biotech developing oral deucrictibant for angioedema attacks. Not ranked · Not scored PRAX Praxis Precision Medicines, Inc. Praxis develops central nervous system drugs for epilepsy and movement disorders and is preparing for its first possible launches. Not ranked · Not scored PVLA Palvella Therapeutics, Inc. Palvella develops topical QTORIN drugs for rare genetic skin and vascular diseases. Not ranked · Not scored RLAY Relay Therapeutics, Inc. Relay is a clinical-stage biotech using its Dynamo platform to design cancer and genetic disease drugs. Not ranked · Not scored RPRX Royalty Pharma plc Royalty Pharma buys drug royalty streams and funds biotech research in return for future sales payments. Not ranked · Not scored RVMD Revolution Medicines, Inc. Revolution Medicines develops oral cancer drugs that target active RAS proteins in tumors. Not ranked · Not scored RYTM Rhythm Pharmaceuticals, Inc. Rhythm sells IMCIVREE, a rare obesity drug aimed at broken MC4R hunger signals. Not ranked · Not scored SION Sionna Therapeutics, Inc. Sionna is a clinical-stage biotech developing cystic fibrosis drugs that aim to stabilize the CFTR protein. Not ranked · Not scored SLNO Soleno Therapeutics, Inc. Soleno sold VYKAT XR for Prader-Willi syndrome before being acquired by Neurocrine. Not ranked · Not scored SLS SELLAS Life Sciences Group, Inc. SELLAS develops cancer drugs, led by GPS and SLS009, but faces heavy financial pressure and has no steady product revenue. Not ranked · Not scored SMMT Summit Therapeutics Inc. Summit is a clinical-stage cancer drug developer built entirely around ivonescimab, a dual-action antibody. Not ranked · Not scored SRRK Scholar Rock Holding Corporation Scholar Rock is a clinical stage biotech trying to launch apitegromab, a muscle drug for spinal muscular atrophy. Not ranked · Not scored SWTX SpringWorks Therapeutics Inc. SpringWorks sells rare disease cancer drugs and is set to be bought by Merck KGaA for cash. Not ranked · Not scored SYRE Spyre Therapeutics, Inc. Spyre is a clinical-stage biotech developing longer-lasting antibody drugs for IBD and immune diseases. Not ranked · Not scored TERN Terns Pharmaceuticals, Inc. Terns is a pre-revenue biotech developing oral drugs for CML and obesity. Not ranked · Not scored TLX Telix Pharmaceuticals Limited Telix sells cancer imaging drugs while building a radiopharmaceutical therapy pipeline. Not ranked · Not scored TNGX Tango Therapeutics, Inc. Tango is a clinical-stage cancer biotech trying to turn synthetic lethality science into targeted drugs. Not ranked · Not scored TRVI Trevi Therapeutics, Inc. Trevi is a clinical-stage biotech developing Haduvio for chronic cough conditions. Not ranked · Not scored VERA Vera Therapeutics, Inc. Vera is a late-stage biotech focused on immune kidney diseases, led by atacicept for IgAN. Not ranked · Not scored VKTX Viking Therapeutics, Inc. Clinical-stage biotech developing obesity, liver disease, and endocrine drugs, with no approved products yet. Not ranked · Not scored VRDN Viridian Therapeutics, Inc. Viridian is a newly commercial biotech launching its first medicine for Thyroid Eye Disease. Not ranked · Not scored VRNA Verona Pharma plc Verona was a respiratory biotech built around Ohtuvayre, a COPD drug now owned by Merck. Not ranked · Not scored XENE Xenon Pharmaceuticals Inc. Xenon is a neuroscience biotech built around Azetukalner for epilepsy, depression, and related brain disorders. Not ranked · Not scored